Xiaolin Wang - 17 Jun 2021 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Role
EVP, Clinical Development
Signature
/s/ Jack Anders, as Attorney-in-fact for Xiaolin Wang
Issuer symbol
RVMD
Transactions as of
17 Jun 2021
Net transactions value
-$8,291
Form type
4
Filing time
22 Jun 2021, 17:19:41 UTC
Next filing
21 Sep 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVMD Common Stock Sale $8,291 -243 -1.9% $34.12 12,445 17 Jun 2021 Direct F1, F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes.
F2 This transaction was executed in multiple trades in prices ranging from $33.37 to $34.22, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3 Includes 744 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2021.
F4 Includes 10,500 RSUs.

Remarks:

EVP, Clinical Development